Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07), Zacks reports.
Aquestive Therapeutics Stock Up 2.2%
Shares of Aquestive Therapeutics stock traded up $0.06 on Monday, reaching $2.85. 1,148,028 shares of the stock were exchanged, compared to its average volume of 1,451,901. The firm has a market capitalization of $283.06 million, a price-to-earnings ratio of -6.33 and a beta of 2.02. Aquestive Therapeutics has a twelve month low of $2.20 and a twelve month high of $5.80. The business has a 50 day moving average price of $2.78 and a two-hundred day moving average price of $3.45.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on AQST. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Finally, Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $10.67.
Get Our Latest Stock Analysis on Aquestive Therapeutics
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
